,,ib  ,union ,calendar ,no4 #dbg  #aadth
 ,,congress  #b;d ,session  ,h4 ,r4     
#cfhj  ,report ,no4 #aad-eec  ,,in ,,the
 ,,house ,,of ,,representatives         
,october #a1 #bjae ,mr4 ,sarbanes       
introduced the following bill2 which was
 referred to the ,committee on ,energy  
and ,commerce  ,may #aj1                
#bjaf;,additional sponsors3 ,mr4        
,bucshon1 ,mr4 ,hultgren1 ,mr4          
,bilirakis1 ,mr4 ,shuster1 and ,ms4     
,mc,sally  ,may #aj1 #bjaf ,reported    
with an amendment1 committed to the     
,committee of the ,whole ,house on the  
,state of the ,union1 and ordered to be 
printed ,strike out all after the       
enacting clause and insert the part     
printed in italic ,for text of          
introduced bill1 see copy of bill as    
introduced on ,october #a1 #bjae  ,a    
,,bill  ,to provide for the ,secretary  
of ,health and ,human ,services to carry
 out a grant program for co-prescribing 
opioid overdose reversal drugs4  #a4    
,short title ,this ,act may be cited as 

the ,co-,prescribing to ,reduce         
,overdoses ,act of #bjaf4  #b4 ,opioid  
overdose reversal drugs prescribing     
grant program  7a7 ,establishment  7#a7 
,in general ,not later than six months  
after the date of the enactment of this 
,act1 the ,secretary of ,health and     
,human ,services may establish1 in      
accordance with this section1 a         
five-year opioid overdose reversal drugs
 prescribing grant program 7in this ,act
 referred to as the grant program74     
7#b7 ,maximum grant amount ,a grant made
 under this section may not be for more 
than #bjj1jjj per grant year4  7#c7     
,eligible entity ,for purposes of this  
section1 the term eligible entity means 
a federally qualified health center 7as 
defined in section #ahfa7;aa7 of the    
,social ,security ,act 7#db ,u4,s4,c4   
#aciex7aa771 an opioid treatment program
 under part #h of title #db1 ,code of   
,federal ,regulations1 any practitioner 
dispensing narcotic drugs pursuant to   
section #cjc7;g7 of the ,controlled     

,substances ,act 7#ba ,u4,s4,c4         
#hbc7;g771 or any other entity that the 
,secretary deems appropriate4  7#d7     
,prescribing ,for purposes of this      
section and section #c1 the term        
prescribing means1 with respect to an   
opioid overdose reversal drug1 such as  
naloxone1 the practice of prescribing   
such drug--  7,a7 in conjunction with an
 opioid prescription for patients at an 
elevated risk of overdose2  7,b7 in     
conjunction with an opioid agonist      
approved under section #eje of the      
,federal ,food1 ,drug1 and ,cosmetic    
,act 7#ba ,u4,s4,c4 #cee7 for the       
treatment of opioid abuse disorder2     
7,c7 to the caregiver or a close        
relative of patients at an elevated risk
 of overdose from opioids2 or  7,d7 in  
other circumstances1 as identified by   
the ,secretary1 in which a provider     
identifies a patient is at an elevated  
risk for an intentional or unintentional
 drug overdose from heroin or           
prescription opioid therapies4  7b7     

,application ,to be eligible to receive 
a grant under this section1 an eligible 
entity shall submit to the ,secretary of
 ,health and ,human ,services1 in such  
form and manner as specified by the     
,secretary1 an application that         
describes--  7#a7 the extent to which   
the area to which the entity will       
furnish services through use of the     
grant is experiencing significant       
morbidity and mortality caused by opioid
 abuse2  7#b7 the criteria that will be 
used to identify eligible patients to   
participate in such program2 and  7#c7  
how such program will work to try to    
identify ,state1 local1 or private      
funding to continue the program after   
expiration of the grant4  7c7 ,use of   
funds ,an eligible entity receiving a   
grant under this section may use the    
grant for any of the following          
activities1 but may use not more than   
#bj percent of the grant funds for      
activities described in paragraphs 7#d7 
and 7#e73  7#a7 ,to establish a program 

for prescribing opioid overdose reversal
 drugs1 such as naloxone4  7#b7 ,to     
train and provide resources for health  
care providers and pharmacists on the   
prescribing of opioid overdose reversal 
drugs1 such as naloxone4  7#c7 ,to      
establish mechanisms and processes for  
tracking patients participating in the  
program described in paragraph 7#a7 and 
the health outcomes of such patients4   
7#d7 ,to purchase opioid overdose       
reversal drugs1 such as naloxone1 for   
distribution under the program described
 in paragraph 7#a74  7#e7 ,to offset the
 co-pays and other cost sharing         
associated with opioid overdose reversal
 drugs1 such as naloxone1 to ensure that
 cost is not a limiting factor for      
eligible patients4  7#f7 ,to conduct    
community outreach1 in conjunction with 
community-based organizations1 designed 
to raise awareness of prescribing       
practices1 and the availability of      
opioid overdose reversal drugs1 such as 
naloxone4  7#g7 ,to establish protocols 

to connect patients who have experienced
 a drug overdose with appropriate       
treatment1 including medication assisted
 treatment and appropriate counseling   
and behavioral therapies4  7d7          
,evaluations by recipients ,as a        
condition of receipt of a grant under   
this section1 an eligible entity shall1 
for each year for which the grant is    
received1 submit to the ,secretary of   
,health and ,human ,services information
 on appropriate outcome measures        
specified by the ,secretary to assess   
the outcomes of the program funded by   
the grant1 including--  7#a7 the number 
of prescribers trained2  7#b7 the number
 of prescribers who have co-prescribed  
an opioid overdose reversal drug1 such  
as naloxone1 to at least one patient2   
7#c7 the total number of prescriptions  
written for opioid overdose reversal    
drugs1 such as naloxone2  7#d7 the      
percentage of patients at elevated risk 
who received a prescription for an      
opioid overdose reversal drug1 such as  

naloxone2  7#e7 the number of patients  
reporting use of an opioid overdose     
reversal drug1 such as naloxone2 and    
7#f7 any other outcome measures that the
 ,secretary deems appropriate4  7e7     
,reports by ,secretary ,for each year of
 the grant program under this section1  
the ,secretary of ,health and ,human    
,services shall submit to the           
appropriate committees of the ,house of 
,representatives and of the ,senate a   
report aggregating the information      
received from the grant recipients for  
such year under subsection 7d7 and      
evaluating the outcomes achieved by the 
programs funded by grants made under    
this section4  #c4 ,providing           
information to prescribers in certain   
,federal health care and medical        
facilities on best practices for        
prescribing opioid overdose reversal    
drugs  7a7 ,in general ,not later than  
#ahj days after the date of enactment of
 this ,act1 the ,secretary of ,health   
and ,human ,services 7in this section   

referred to as the ,secretary7 may1 as  
appropriate1 provide information to     
prescribers within ,federally qualified 
health centers 7as defined in paragraph 
7#d7 of section #ahfa7;aa7 of the       
,social ,security ,act 7#db ,u4,s4,c4   
#aciex7aa7771 and the health care       
facilities of the ,indian ,health       
,service1 on best practices for         
prescribing opioid overdose reversal    
drugs1 such as naloxone1 for patients   
receiving chronic opioid therapy1       
patients being treated for opioid use   
disorders1 and other patients that a    
provider identifies as having an        
elevated risk of overdose from heroin or
 prescription opioid therapies4  7b7    
,not establishing a medical standard of 
care ,the information on best practices 
provided under this section shall not be
 construed as constituting or           
establishing a medical standard of care 
for prescribing opioid overdose reversal
 drugs1 such as naloxone1 for patients  
described in subsection 7a74  7c7 ,no   

authorization of any additional         
appropriations ,the ,secretary shall    
carry out this section through funds    
otherwise appropriated and nothing in   
this section shall be construed as      
authorizing the appropriations of       
additional funds to carry out this      
section4  7d7 ,elevated risk of overdose
 defined ,in this section1 the term     
elevated risk of overdose has the       
meaning given such term by the          
,secretary1 which-- 7#a7 may be based on
 the criteria provided in the ,opioid   
,overdose ,toolkit published by the     
,substance ,abuse and ,mental ,health   
,services ,administration 7,,samhsa72   
and  7#b7 may include patients on a     
first course opioid treatment1 patients 
using extended-release and long-acting  
opioid analgesics1 and patients with a  
respiratory disease or other            
co-morbidities4  #d4 ,authorization of  
appropriations ,there is authorized to  
be appropriated to carry out this ,act  
#e1jjj1jjj for the period of fiscal     

years #bjag through #bjba4  #e4 ,cut-,go
 ,compliance ,subsection 7f7 of section 
#cai;,d of the ,public ,health ,service 
,act 7#db ,u4,s4,c4 #bdg;d-#d7 is       
amended by inserting before the period  
at the end the following3 7except such  
dollar amount shall be reduced by       
#e1jjj1jjj for fiscal year #bjah74  ,may
 #aj1 #bjaf ,reported with an amendment1
 committed to the ,committee of the     
,whole ,house on the ,state of the      
,union1 and ordered to be printed